• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在肝脏中特异性表达 Pim-3 转基因的小鼠中加速肝细胞癌的发展。

Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.

机构信息

Department of Hematology and Hematology research Laboratory, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR China.

出版信息

Oncogene. 2010 Apr 15;29(15):2228-37. doi: 10.1038/onc.2009.504. Epub 2010 Jan 18.

DOI:10.1038/onc.2009.504
PMID:20101231
Abstract

Pim-3, a proto-oncogene with serine/threonine kinase activity, was enhanced in hepatocellular carcinoma (HCC) tissues. To address the roles of Pim-3 in HCC development, we prepared transgenic mice that express human Pim-3 selectively in liver. The mice were born at a Mendelian ratio, were fertile and did not exhibit any apparent pathological changes in the liver until 1 year after birth. Pim-3-transgenic mouse-derived hepatocytes exhibited accelerated cell cycle progression. The administration of a potent hepatocarcinogen, diethylnitrosamine (DEN), induced accelerated proliferation of liver cells in Pim-3 transgenic mice in the early phase, compared with that observed for wild-type mice. Treatment with DEN induced lipid droplet accumulation with increased proliferating cell numbers 6 months after the treatment. Eventually, wild-type mice developed HCC with a frequency of 40% until 10 month after the treatment. Lipid accumulation was accelerated in Pim-3 transgenic mice with higher proliferating cell numbers, compared with that observed for wild-type mice. Pim-3 transgenic mice developed HCC with a higher incidence (80%) and a heavier burden, together with enhanced intratumoral CD31-positive vascular areas, compared with that observed for wild-type mice. These observations indicate that Pim-3 alone cannot cause, but can accelerate HCC development when induced by a hepatocarcinogen, such as DEN.

摘要

Pim-3,一种具有丝氨酸/苏氨酸激酶活性的原癌基因,在肝癌(HCC)组织中增强。为了研究 Pim-3 在 HCC 发展中的作用,我们制备了选择性在肝脏中表达人 Pim-3 的转基因小鼠。这些小鼠以孟德尔比例出生,具有生育能力,并且在出生后 1 年内肝脏没有出现任何明显的病理变化。Pim-3 转基因小鼠来源的肝细胞表现出加速的细胞周期进程。强效肝癌诱导剂二乙基亚硝胺(DEN)的给药在早期诱导 Pim-3 转基因小鼠的肝细胞加速增殖,而在野生型小鼠中观察到的增殖则较慢。DEN 处理 6 个月后,诱导了脂滴积累和增殖细胞数量的增加。最终,野生型小鼠在 DEN 处理后 10 个月时发展为 HCC 的频率为 40%。与野生型小鼠相比,Pim-3 转基因小鼠中的脂滴积累加速,且增殖细胞数量更多。Pim-3 转基因小鼠发展为 HCC 的发生率(80%)更高,肿瘤负担更重,并且肿瘤内 CD31 阳性血管区域增强,与野生型小鼠相比。这些观察结果表明,Pim-3 本身不能引起 HCC,但在 DEN 等肝癌诱导剂的诱导下可以加速 HCC 的发展。

相似文献

1
Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.在肝脏中特异性表达 Pim-3 转基因的小鼠中加速肝细胞癌的发展。
Oncogene. 2010 Apr 15;29(15):2228-37. doi: 10.1038/onc.2009.504. Epub 2010 Jan 18.
2
Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines.丝氨酸/苏氨酸激酶Pim-3在肝细胞癌发生中的异常表达及其在人肝癌细胞系增殖中的作用。
Int J Cancer. 2005 Mar 20;114(2):209-18. doi: 10.1002/ijc.20719.
3
Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice.肝细胞癌源于转基因小鼠中细胞周期蛋白D1的慢性过度表达。
Cancer Res. 2001 Jul 15;61(14):5389-95.
4
Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell.丝氨酸/苏氨酸激酶Pim-2通过介导肝细胞存活和防止其凋亡来促进肝肿瘤发生诱导。
J Surg Res. 2009 May 1;153(1):17-22. doi: 10.1016/j.jss.2008.03.033. Epub 2008 Apr 22.
5
Roles of Pim-3, a novel survival kinase, in tumorigenesis.Pim-3,一种新型生存激酶,在肿瘤发生中的作用。
Cancer Sci. 2011 Aug;102(8):1437-42. doi: 10.1111/j.1349-7006.2011.01966.x. Epub 2011 May 23.
6
Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha.Bcl-2可延迟并改变由转化生长因子α诱导的肝癌发生。
Cancer Res. 2001 Jan 15;61(2):594-601.
7
Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis.肝细胞特异性成纤维细胞生长因子21的强制表达延迟了化学诱导肝癌发生的起始。
Mol Carcinog. 2006 Dec;45(12):934-42. doi: 10.1002/mc.20241.
8
The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice.AP-1 抑制蛋白 JDP2 增强了小鼠的肝细胞癌。
Mol Cancer. 2010 Mar 9;9:54. doi: 10.1186/1476-4598-9-54.
9
Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.共表达c-myc和转化生长因子-α的转基因小鼠肝脏中肿瘤发生的演变
Am J Pathol. 1996 Aug;149(2):407-28.
10
Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis.锌指蛋白GFI-1具有较低的致癌潜能,但在T细胞淋巴瘤发生过程中与pim和myc基因有很强的协同作用。
Oncogene. 1998 Nov 19;17(20):2661-7. doi: 10.1038/sj.onc.1202191.

引用本文的文献

1
PIM3 Kinase: A Promising Novel Target in Solid Cancers.PIM3激酶:实体癌中一个有前景的新型靶点。
Cancers (Basel). 2024 Jan 26;16(3):535. doi: 10.3390/cancers16030535.
2
miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.miR-200c-3p、miR-222-5p 和 miR-512-3p 构成了索拉非尼治疗晚期肝细胞癌疗效的生物标志物特征。
Cells. 2022 Aug 28;11(17):2673. doi: 10.3390/cells11172673.
3
CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
CRISPR/Cas9 介导的 PIM3 基因敲除抑制人肝癌细胞的肿瘤发生和肿瘤干细胞特性。
Cancer Gene Ther. 2022 May;29(5):558-572. doi: 10.1038/s41417-021-00334-4. Epub 2021 Apr 16.
4
PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.PIM447 抑制肝癌的癌变并增强顺铂的疗效。
J Pediatr Surg. 2021 Jun;56(6):1157-1164. doi: 10.1016/j.jpedsurg.2021.02.039. Epub 2021 Feb 24.
5
The kinase polypharmacology landscape of clinical PARP inhibitors.临床 PARP 抑制剂的激酶多靶性药理学特征。
Sci Rep. 2020 Feb 17;10(1):2585. doi: 10.1038/s41598-020-59074-4.
6
Familial association of lung cancer with liver cancer in first-degree relatives.肺癌与一级亲属患肝癌之间的家族关联性。
Cancer Manag Res. 2019 Jun 28;11:5813-5819. doi: 10.2147/CMAR.S199462. eCollection 2019.
7
The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.PIM3 的存在增加了肝母细胞瘤的肿瘤发生和肿瘤起始细胞表型,并与患者生存率降低相关。
J Pediatr Surg. 2019 Jun;54(6):1206-1213. doi: 10.1016/j.jpedsurg.2019.02.029. Epub 2019 Feb 28.
8
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.靶向PIM激酶影响肝母细胞瘤中CD133肿瘤细胞群体的维持。
Transl Oncol. 2019 Feb;12(2):200-208. doi: 10.1016/j.tranon.2018.10.008. Epub 2018 Nov 6.
9
PIM Kinase as an Executional Target in Cancer.PIM激酶作为癌症中的一个执行靶点。
J Cancer Prev. 2018 Sep;23(3):109-116. doi: 10.15430/JCP.2018.23.3.109. Epub 2018 Sep 30.
10
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.将PIM激酶作为人肝母细胞瘤的一种治疗策略
Oncotarget. 2018 Apr 27;9(32):22665-22679. doi: 10.18632/oncotarget.25205.